EOC
MCID: OVR094
MIFTS: 39

Ovarian Epithelial Cancer (EOC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 20 6
Epithelial Ovarian Cancer 20 70
Ovarian Epithelial Carcinoma 20
Ovarian Cancer, Epithelial 20
Eoc 20

Classifications:



External Ids:

UMLS 70 C0677886

Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to lung cancer susceptibility 3 and ovarian cancer. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Doxorubicin and Liposomal doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and endothelial.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 30.3 PIK3CA HOTAIR H19 CCAT1
2 ovarian cancer 30.3 PIK3CA HOTAIR HAGLR H19 ERLNC1 DNM3OS
3 leukemia, acute myeloid 30.2 PIK3CA MIR432 MIR376A1 MIR337 HOTAIR CCAT1
4 thyroid carcinoma 30.1 PIK3CA HOTAIR H19
5 gastric adenocarcinoma 30.1 PIK3CA HOTAIR H19
6 squamous cell carcinoma 30.0 PIK3CA HOTAIR H19 CCAT2
7 kidney cancer 30.0 PIK3CA HOTAIR H19
8 osteogenic sarcoma 30.0 HOTAIR H19 CCAT2 CCAT1
9 cervical cancer 29.9 PIK3CA HOTAIR HAGLR H19 CCAT2 CCAT1
10 nasopharyngeal carcinoma 29.9 PIK3CA HOTAIR H19 CCAT1
11 oral squamous cell carcinoma 29.7 MIRLET7A3 MIR376C MIR337 HOTAIR H19 CCAT2
12 gastric cancer 29.0 PIK3CA HOTAIR HAGLR H19 DLEU1 CCAT2
13 malignant epithelial tumor of ovary 11.4
14 ovarian clear cell carcinoma 11.2
15 ovary transitional cell carcinoma 11.1
16 primary peritoneal carcinoma 11.0
17 neutropenia 10.9
18 adenocarcinoma 10.6
19 alopecia 10.6
20 fallopian tube carcinoma 10.6
21 thrombocytosis 10.6
22 peripheral nervous system disease 10.6
23 neuropathy 10.5
24 thrombocytopenia 10.5
25 clear cell adenocarcinoma 10.5
26 ovarian disease 10.4
27 mucinous adenocarcinoma 10.4
28 mucinous cystadenocarcinoma 10.4
29 appendix adenocarcinoma 10.4
30 infertility 10.4
31 ileus 10.4
32 insulin-like growth factor i 10.4
33 body mass index quantitative trait locus 1 10.4
34 lynch syndrome 10.4
35 epileptic encephalopathy, childhood-onset 10.3
36 ovarian serous carcinoma 10.3
37 pelvic inflammatory disease 10.3
38 diarrhea 10.3
39 sensory peripheral neuropathy 10.3
40 stomatitis 10.3
41 granulocytopenia 10.3
42 familial ovarian cancer 10.3
43 endometriosis of ovary 10.3
44 constipation 10.3
45 ovarian cystadenoma 10.3
46 adenoma 10.3
47 b-cell lymphoma 10.3
48 cytokine deficiency 10.3
49 acute sensory ataxic neuropathy 10.3
50 nemaline myopathy 10.3 MIR432 MIR376C MIR376A1

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
2
Liposomal doxorubicin Phase 4 31703
3 Antibiotics, Antitubercular Phase 4
4 Anti-Bacterial Agents Phase 4
5
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
6
Gemcitabine Approved Phase 3 95058-81-4 60750
7
Sodium citrate Approved, Investigational Phase 3 68-04-2
8
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
9
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
10
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
11
Lenograstim Approved, Investigational Phase 3 135968-09-1
12
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
13
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
14
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
15
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
16
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
17
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
18
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
19
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
21
Molgramostim Investigational Phase 3 99283-10-0
22
Abagovomab Investigational Phase 2, Phase 3 792921-10-9
23 Antineoplastic Agents, Immunological Phase 3
24 Anti-Infective Agents Phase 3
25 Antiviral Agents Phase 3
26 Immunosuppressive Agents Phase 3
27 Antimetabolites Phase 3
28 DHEA (Dehydroepiandrosterone) Phase 3
29 Citrate Phase 3
30 Hormone Antagonists Phase 3
31 Hormones Phase 3
32 Estrogen Receptor Antagonists Phase 3
33 Estrogens Phase 3
34 Estrogen Antagonists Phase 3
35 Adjuvants, Immunologic Phase 3
36 Sunflower Phase 3
37 Anesthetics, Local Phase 3
38 Anesthetics Phase 3
39 Aromatase Inhibitors Phase 3
40 topoisomerase I inhibitors Phase 3
41 Hematinics Phase 3
42 Epoetin alfa Phase 3 113427-24-0
43
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
44
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
45
Fondaparinux Approved, Investigational Phase 2 104993-28-4
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
47
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 5330286 11431660
48
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
49
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
50
Itraconazole Approved, Investigational Phase 1, Phase 2 84625-61-6 55283

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
2 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
3 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
4 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
5 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
6 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study Unknown status NCT02681432 Phase 3 HIPEC
7 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
8 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Completed NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
9 Randomized Trial of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Completed NCT01091636 Phase 2, Phase 3
10 An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL) Completed NCT00989131 Phase 3 Paclical®;Taxol®
11 FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Completed NCT02631876 Phase 3 Mirvetuximab soravtansine;Paclitaxel;Pegylated liposomal doxorubicin;Topotecan
12 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
13 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
14 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
15 A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
16 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
17 Phase 2/3 Study of Masitinib in Combination With Gemcitabine Versus Gemcitabine Alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line Completed NCT02490488 Phase 2, Phase 3 Masitinib;Gemcitabine;Placebo
18 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
19 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
20 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
21 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
22 A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery Completed NCT00003695 Phase 3 chemotherapy
23 A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
24 A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression Completed NCT01684878 Phase 3 Gemcitabine (Chemotherapy);Paclitaxel (Chemotherapy);Pertuzumab;Placebo;Topotecan (Chemotherapy)
25 Randomized Phase III Trial of the Need for Adjuvant Chemotherapy in Stage I Epithelial Ovarian Cancer After Comprehensive Staging Surgery Recruiting NCT04063527 Phase 3 adjuvant chemotherapy
26 MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Recruiting NCT04209855 Phase 3 Mirvetuximab Soravtansine;Paclitaxel;Topotecan;Pegylated liposomal doxorubicin
27 A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery Recruiting NCT03373058 Phase 3 adjuvant chemotherapy
28 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer Recruiting NCT02859038 Phase 3
29 Long-acting Granulocyte Colony Stimulating Factor for the Prevention Febrile Neutropenia in Epithelial Ovarian Cancer: A Phase 3 Randomized Control Study Recruiting NCT03740464 Phase 3 long-acting granulocyte colony stimulating factor;Short-term granulocyte colony stimulating factor
30 SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Recruiting NCT04296890 Phase 3 Mirvetuximab Soravtansine
31 Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
32 EXemestane in Progesterone and/or Estrogen Receptor Positive Epithelial Ovarian Cancer: A Randomized Phase III Trial, EXPERT Recruiting NCT04460807 Phase 3 Exemestane
33 A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib;Docetaxel
34 Long-acting Versus Short-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Patients: A Multicenter Phase 3 Randomized Controlled Study Recruiting NCT04101760 Phase 3 Long-acting granulocyte colony stimulating factor;Short-acting granulocyte colony stimulating factor
35 A Randomized Double Blind, Multicenter Trial to Assess Time-interval Between Cytoreductive Surgery and Adjuvant Chemotherapy After Administration of Local Anesthetic Intraperitoneally/Perioperatively in Advanced Epithelial Ovarian Cancer Recruiting NCT04065009 Phase 3 Ropivacaine;Saline Solution
36 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study). Recruiting NCT04111978 Phase 3 Letrozole 2.5mg
37 A Phase III Clinical Trail of Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Active, not recruiting NCT03371693 Phase 3
38 ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) Active, not recruiting NCT03522246 Phase 3 Rucaparib;Nivolumab;Placebo Oral Tablet;Placebo IV Infusion
39 A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy Active, not recruiting NCT03106987 Phase 3 Active Comparator: Olaparib tablets;Placebo
40 A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT01506856 Phase 2, Phase 3 Paclitaxel(intravenous) + Carboplatin(intravenous);Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
41 ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer Active, not recruiting NCT03602859 Phase 3 Niraparib;Dostarlimab (TSR-042);Placebo;Standard of care;Dostarlimab/Placebo;Niraparib/Placebo
42 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Active, not recruiting NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
43 PHASE III RANDOMIZED CONTROL CASE STUDY OF LETROZOLE IN WOMEN WITH HEAVILY PRETREATED OVARIAN CANCER (MITO 32) Not yet recruiting NCT04421547 Phase 3 Letrozole 2.5mg;Standard single agent chemotherapy
44 A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of HIPEC as NACT and Postoperative Chemotherapy After Interval Debulking Surgery in the Treatment of Advanced-Stage Epithelial Ovarian Cancer Not yet recruiting NCT03180177 Phase 3 neoadjuvant chemotherapy;adjuvant chemotherapy
45 Stratified Evaluation and Prediction of Survival Benefit for PDS or NACT-IDS in Advanced Ovarian Cancer, A Randomized, Phase 3 Trial After the SUNNY Study Not yet recruiting NCT04515602 Phase 3 PARPi
46 Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer Not yet recruiting NCT03220932 Phase 3 Chemotherapy and bevacizumab (CT-BEV)
47 Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy Not yet recruiting NCT03772028 Phase 3 cisplatin
48 A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer Suspended NCT01376752 Phase 3 HIPEC
49 A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX® Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy Terminated NCT01840943 Phase 3 CAELYX;Topotecan HCl
50 Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum Terminated NCT00189371 Phase 3 paclitaxel, carboplatin, epoetin alpha

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

40
Ovary, Lymph Node, Endothelial, T Cells, Neutrophil, Myeloid, Lung

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 9952)
# Title Authors PMID Year
1
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
2
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
3
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
4
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
5
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
6
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
7
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
8
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. 61 47
18458333 2008
9
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. 61 47
17974952 2007
10
MicroRNA signatures in human ovarian cancer. 61 47
17875710 2007
11
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 6
17673550 2007
12
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 6
15608678 2005
13
Mutation of the PIK3CA gene in ovarian and breast cancer. 6
15520168 2004
14
High frequency of mutations of the PIK3CA gene in human cancers. 6
15016963 2004
15
Circular RNA ABCB10 promotes cell proliferation and invasion, but inhibits apoptosis via regulating the microRNA‑1271‑mediated Capn4/Wnt/β‑catenin signaling pathway in epithelial ovarian cancer. 61
33760208 2021
16
Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission. 61
33664128 2021
17
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. 61
33705695 2021
18
RETRACTED ARTICLE: Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer. 61
31811526 2021
19
Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. 61
33137377 2021
20
Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review. 61
33037532 2021
21
TGFβ signaling networks in ovarian cancer progression and plasticity. 61
33590419 2021
22
The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study. 61
33420762 2021
23
Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies. 61
33563649 2021
24
Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications. 61
33436287 2021
25
Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. 61
33506580 2021
26
Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients. 61
33161412 2021
27
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. 61
33581846 2021
28
Risk of second malignancy in patients with ovarian clear cell carcinoma. 61
33443021 2021
29
Dynamic prediction of disease processes based on recurrent history and functional principal component analysis of longitudinal biomarkers: Application for ovarian epithelial cancer. 61
33484015 2021
30
Development and validation of nomograms for epithelial ovarian cancer: a SEER population-based, real-world study. 61
33533669 2021
31
DNA methylome profiling identifies novel methylated genes in epithelial ovarian cancer patients with platinum resistance. 61
33403724 2021
32
Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea. 61
33638309 2021
33
Comparison of the survival outcomes of laparoscopy versus laparotomy in treatment of early-stage ovarian cancer: a systematic review and meta-analysis. 61
33726795 2021
34
Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. 61
33686173 2021
35
A polygenic methylation prediction model associated with response to chemotherapy in epithelial ovarian cancer. 61
33738340 2021
36
EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis. 61
33726845 2021
37
Soluble forms of immune checkpoints in ovarian cancer. 61
33734640 2021
38
MiR-520a-3p inhibits malignant progression of epithelial ovarian cancer by targeting SUV39H1 expression. 61
33196969 2021
39
Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach? 61
33038519 2021
40
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. 61
33683525 2021
41
Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients. 61
33327048 2021
42
Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group. 61
33806443 2021
43
Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer. 61
33715894 2021
44
Low FOXJ2 expression is associated with unfavorable postoperative prognosis of patients with epithelial ovarian cancer. 61
33725831 2021
45
Circulating CD14+ HLA-DRlo/- monocytic cells as a biomarker for epithelial ovarian cancer progression. 61
32905653 2021
46
A literature review on function and regulation mechanism of DKK4. 61
33586359 2021
47
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. 61
33398064 2021
48
MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc. 61
33804458 2021
49
Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy. 61
33799991 2021
50
Dietitian encounters after treatment for ovarian cancer. 61
33749900 2021

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys) SNV Pathogenic 13657 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
2 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic 13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
3 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

GO Terms for Ovarian Epithelial Cancer

Biological processes related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.28 MIRLET7A3 MIR495 MIR432 MIR377 MIR376C MIR376B
2 negative regulation of sprouting angiogenesis GO:1903671 8.96 MIR495 MIR377

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....